[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lynch-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lynch-syndrome":45},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,41,0,25,[9,101,130,156,228,254,277,299,329,351,369,394,420,446,469,531,553,573,607,637,662,687,711,749,779],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":78,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":100},"100210159","integrated-cancer-repository-for-cancer-research-100210159",false,"NCT02012699","Integrated Cancer Repository for Cancer Research","iCaRe2","Inclusion Criteria\n\n* Diagnosis\u002Fhistory of cancer\n* Risk for developing cancer or suspicious clinical findings\n* No history of cancer (normal control registry)\n* Able to provide informed consent\n* 19 years of age or older\n* English or Spanish speaking individuals\n\nExclusion Criteria\n\n* Unable to provide informed consent because of cognitive impairment\n* Non-English or non-Spanish speaking individuals",true,"ALL","19 Years","110 Years",{"count":22,"type":23},999999,"ESTIMATED","80 Years","OBSERVATIONAL","The iCaRe2 is a multi-institutional resource created and maintained by the Fred \\& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77],"Pancreatic Cancer","Thyroid Cancer","Lung Cancer","Esophageal Cancer","Thymus Cancer","Colon Cancer","Rectal Cancer","Gastrointestinal Stromal Tumors","Anal Cancer","Bile Duct Cancer","Duodenal Cancer","Gallbladder Cancer","Gastric Cancer","Liver Cancer","Small Intestine Cancer","Peritoneal Surface Malignancies","Familial Adenomatous Polyposis","Lynch Syndrome","Bladder Cancer","Kidney Cancer","Penile Cancer","Prostate Cancer","Testicular Cancer","Ureter Cancer","Urethral Cancer","Hypopharyngeal Cancer","Laryngeal Cancer","Lip Cancer","Oral Cavity Cancer","Nasopharyngeal Cancer","Oropharyngeal Cancer","Paranasal Sinus Cancer","Nasal Cavity Cancer","Salivary Gland Cancer","Skin Cancer","Central Nervous System Tumor","Central Nervous System Cancer","Mesothelioma","Breast Cancer","Leukemia","Melanoma","Sarcoma","Unknown Primary Tumor","Multiple Myeloma","Ovarian Cancer","Endometrial Cancer","Vaginal Cancer","Neuroendocrine Tumors","Plasma Cell Dyscrasia","Healthy Control",[28,29,79,80,81,82,83,84,85,86,66,87,76,77],"Esophageal cancer","Thymus cancer","Pancreatic tumor","Esophageal tumor","Thymus tumor","Thyroid Tumor","Thyroid Nodule","Lung Tumor","Neuroendocrine tumor","RECRUITING","2026-06-25",{"date":91,"type":92},"2026-06-29","ACTUAL",{"date":94,"type":92},"2013-11-01",{"date":96,"type":23},"2099-12",{"name":98,"class":99},"University of Nebraska","OTHER",42,{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":12,"sex":18,"minAge":108,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":111,"phases":112,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":129},"100616319","overcoming-barriers-to-uptake-of-cascade-screening-100616319","NCT07304063","Overcoming Barriers to Uptake of Cascade Screening","Let's Talk: Overcoming Barriers to Uptake of Cascade Screening Through a Stakeholder-informed Online Intervention","Inclusion Criteria for Patients\n\n* Written informed consent obtained to participate in the study.\n* Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.\n* Age ≥ 18 years at the time of consent.\n* Written informed consent obtained to participate in the study.\n* Self-reported Lynch syndrome diagnosis.\n\nInclusion Criteria for Genetic Counselor\n\n* Written informed consent obtained to participate in the study.\n* Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.\n* Age ≥ 18 years at the time of consent.\n* Written informed consent obtained to participate in the study.\n* Self-reported employment as a practicing genetic counselor at a medical institution.\n\nExclusion Criteria for Patients\n\n* The patient has already notified all relatives about their diagnosis with Lynch syndrome.\n\nExclusion Criteria for Genetic Counselor\n\n* Genetic Counselor is not employed.","18 Years",{"count":110,"type":23},20,"INTERVENTIONAL",[113],"NA","Lynch syndrome is a genetic condition that increases cancer risk. The public health impact of genetic testing for disease prevention hinges on cascade screening, which is the systematic identification and testing of blood relatives after a family member has been diagnosed with a genetic condition. Despite its importance in disease prevention, only half of first-degree relatives of individuals with Lynch syndrome undergo cascade screening. To address this gap, the study will pilot test an online version of Let's Talk, a novel intervention designed to support and promote cascade screening. This intervention tool is designed to support and encourage more family members to get screened. The purpose of this study aim is to assess the feasibility of the online Let's Talk tool in clinical use by examining implementation and effectiveness outcomes related to the use of the planning tool across three clinics at a large academic-affiliated medical center with patients (n=15) seen by one of five genetic counselors (n=5).",[45],[117,118],"Screening","cascade screening","NOT_YET_RECRUITING","2026-06-22",{"date":122,"type":92},"2026-06-23",{"date":124,"type":23},"2026-07",{"date":126,"type":23},"2026-10",{"name":128,"class":99},"UNC Lineberger Comprehensive Cancer Center",1,{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":111,"phases":139,"briefSummary":140,"conditions":141,"keywords":145,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":129},"100608396","determining-the-prevalence-of-muir-torre-syndrome-in-patients-with-lynch-syndrome-100608396","NCT07201012","Determining the Prevalence of Muir-Torre Syndrome in Patients With Lynch Syndrome","SMT-SL","Inclusion Criteria:\n\n* Patient with a germline alteration of one of the MMR (MisMatch Repair) pathway genes (MLH1, PMS2, MSH2, MSH6) proven by constitutional genetic analysis (genetically authenticated Lynch syndrome).\n* Patient followed at Nîmes University Hospital.\n* Patient having given free and informed consent.\n* Person affiliated to or benefiting from a social security scheme.\n\nExclusion Criteria:\n\n* Person under court protection, guardianship or curatorship.\n* A person who is unable to give consent.\n* Person for whom it is impossible to give informed information.",{"count":138,"type":23},150,[113],"The main aim of this study is to determine the prevalence of Muir-Torre syndrome (MTS) in the population of patients with Lynch syndrome (LS) confirmed by genetic analysis. Other aims include describing the dermatological clinical manifestations of these patients in order to describe any possible new cutaneous manifestations of this syndrome. Another aim is to use molecular biology (microsatellite instability) and immunohistochemistry to analyze non-sebaceous skin lesions and deep-seated tumors that do not belong to the narrow spectrum of Lynch syndrome, and determine whether their occurrence in these patients is related to the genetic syndrome. The follow-up of these tumors (screening for new tumors) in patients with SL, as recommended by the learned societies, will also be evaluated. Finally, a biobank of cutaneous and deep tumour lesions in paraffin (retrospective) and smears of cutaneous lesions and healthy tissue (prospective) will be set up.",[142,143,45,144],"Basal Cell Carcinoma of Skin, Site Unspecified","Epidermoid Carcinoma","Muir-Torre Syndrome",[146,117,147],"Carcinoma","Skin cancer","2026-06-17",{"date":120,"type":92},{"date":151,"type":92},"2026-03-13",{"date":153,"type":23},"2027-12",{"name":155,"class":99},"Centre Hospitalier Universitaire de Nīmes",{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":165,"conditions":166,"keywords":210,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":129},"100289631","familial-investigations-of-childhood-cancer-predisposition-100289631","NCT03050268","Familial Investigations of Childhood Cancer Predisposition","SJFAMILY","NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for this study as shown below, you may enroll regardless of the results of your clinical genetic testing.\n\nDEFINITION OF FAMILIAR CANCER FOR THIS PROTOCOL:\n\nIn this protocol, the definition of \"Familial Cancer\" is met if any of the following is present:\n\n* An individual with a history of cancer diagnosed under 26 years of age who has at least one first, second or third degree relative with a history of cancer diagnosed under 51 years of age; OR\n* An individual who has been diagnosed with more than one cancer, at least one of which was diagnosed under 26 years of age; OR\n* An individual with a clinical or molecular diagnosis of a known cancer predisposition syndrome; OR\n* An individual with a congenital cancer diagnosed before 6 months of age; OR\n* An individual with a rare pediatric cancer or tumor diagnosed before 26 years of age\n\nº Excluding human papilloma virus-associated cervical cancer and non-melanoma skin cancer occurring in adults.\n\nINCLUSION CRITERIA:\n\n* An individual who meets this protocol's definition of \"Familial Cancer,\" as above.\n* Biologic relatives of an individual meeting this protocol's definition of \"Familial Cancer,\" who are either affected or unaffected by cancer.\n\nEXCLUSION CRITERIA:\n\n* An inability or unwillingness of the research participant or his\u002Fher legally authorized representative (LAR) to provide written informed consent.\n* The participant has received allogeneic bone marrow transplantation and has NO pre-transplant germline (cancer-unaffected) DNA available AND is unwilling to provide a skin sample.",{"count":164,"type":23},1500,"NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for this study as shown in the Eligibility Section, you may enroll regardless of the results of your clinical genetic testing.\n\nWhile it is well recognized that hereditary factors contribute to the development of a subset of human cancers, the cause for many cancers remains unknown. The application of next generation sequencing (NGS) technologies has expanded knowledge in the field of hereditary cancer predisposition. Currently, more than 100 cancer predisposing genes have been identified, and it is now estimated that approximately 10% of all cancer patients have an underlying genetic predisposition.\n\nThe purpose of this protocol is to identify novel cancer predisposing genes and\u002For genetic variants. For this study, the investigators will establish a Data Registry linked to a Repository of biological samples. Health information, blood samples and occasionally leftover tumor samples will be collected from individuals with familial cancer. The investigators will use NGS approaches to find changes in genes that may be important in the development of familial cancer. The information gained from this study may provide new and better ways to diagnose and care for people with hereditary cancer.\n\nPRIMARY OBJECTIVE:\n\n* Establish a registry of families with clustering of cancer in which clinical data are linked to a repository of cryopreserved blood cells, germline DNA, and tumor tissues from the proband and other family members.\n\nSECONDARY OBJECTIVE:\n\n* Identify novel cancer predisposing genes and\u002For genetic variants in families with clustering of cancer for which the underlying genetic basis is unknown.",[167,168,169,170,171,172,173,174,175,176,177,178,179,44,180,181,182,183,184,185,186,187,188,189,45,190,191,192,193,194,195,196,197,198,199,200,28,201,202,203,204,205,206,207,208,209],"Acute Leukemia","Adenomatous Polyposis","Adrenocortical Carcinoma","AML","BAP1 Tumor Predisposition Syndrome","Carney Complex","Choroid Plexus Carcinoma","Constitutional Mismatch Repair Deficiency Syndrome","Diamond-Blackfan Anemia","DICER1 Syndrome","Dyskeratosis Congenita","Emberger Syndrome","Familial Acute Myeloid Leukemia","Fanconi Anemia","Familial Cancer","Familial Wilms Tumor","Familial Neuroblastoma","GIST","Hereditary Breast and Ovarian Cancer","Hereditary Paraganglioma-Pheochromocytoma Syndrome","Hodgkin Lymphoma","Juvenile Polyposis","Li-Fraumeni Syndrome","MDS","Melanoma Syndrome","Multiple Endocrine Neoplasia Type 1","Multiple Endocrine Neoplasia Type 2","Neuroblastoma","Neurofibromatosis Type 1","Neurofibromatosis Type II","Nevoid Basal Cell Carcinoma Syndrome","Non Hodgkin Lymphoma","Noonan Syndrome and Other Rasopathy","Overgrowth Syndromes","Peutz-Jeghers Syndrome","Pheochromocytoma\u002FParaganglioma","PTEN Hamartoma Tumor Syndrome","Retinoblastoma","Rhabdoid Tumor Predisposition Syndrome","Rhabdomyosarcoma","Rothmund-Thomson Syndrome","Tuberous Sclerosis","Von Hippel-Lindau Disease",[211,212,213,214,215,216,217,218,219],"Familial cancer","Genetic predisposition","Heritable disease","Cancer risk","Genome analysis","Genetic modifiers","Next generation sequencing (NGS)","Genetic counseling","DNA","2026-06-15",{"date":148,"type":92},{"date":223,"type":92},"2017-04-06",{"date":225,"type":23},"2037-03-31",{"name":227,"class":99},"St. Jude Children's Research Hospital",{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":17,"sex":236,"minAge":108,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":111,"phases":238,"briefSummary":239,"conditions":240,"keywords":242,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":129},"100609873","menstrual-cup-for-early-endometrial-cancer-detection-in-lynch-syndrome-100609873","NCT07220239","Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome","Menstrual Cup-based Endometrial Collection as an Alternative to Endometrial Biopsy in Lynch Syndrome Patients","SCREEN-CUP","Pre-pilot study\n\nInclusion criteria:\n\n* Individuals over the age of 18\n* Menstruating\n\nExclusion criteria:\n\n* Levonorgestrel intrauterine device (IUD) in situ or removed within the last 30 days prior to sample collection\n* Patients with prior endometrial ablation\n* Prior history of endometrial cancer or endometrial intraepithelial neoplasia\n* History of germline pathologic germline variant in MLH1, MSH2, MSH6, PMS2, or EPCAM\n* Known allergy against menstrual cup material (silicone)\n\nMain Study Inclusion criteria\n\n* LS carrier with a pathogenic or likely pathogenic germline variant in MLH1, MSH2, MSH6, PMS2, or EPCAM\n* Individuals over the age of 18\n* Planned screening EMB\n* Menstruating\n* Ability to give consent\n\nExclusion criteria:\n\n* Current pregnancy\n* Levonorgestrel IUD in situ or removed within the last 30 days prior to sample collection\n* Patients with prior endometrial ablation\n* Prior history of endometrial cancer\n* Known allergy against menstrual cup material (silicone)","FEMALE",{"count":7,"type":23},[113],"Study Goal:\n\nThis pilot study wants to find out if using a menstrual cup can be a good, non-invasive way to collect samples from the lining of the uterus (called the endometrium) to help screen for endometrial cancer. This is especially important for women who have a higher chance of getting this cancer, such as those with a genetic condition called Lynch syndrome.\n\nMain Questions the Study Will Answer:\n\n1. Can a menstrual cup collect enough uterine lining (endometrial tissue) for doctors to examine under a microscope?\n2. Are the samples from the menstrual cup as useful for diagnosis as samples taken using the usual method (called an endometrial biopsy or EMB)?\n3. Is using a menstrual cup at home easy, effective, and comfortable for participants?\n4. Can scientists grow small lab models of the uterus (called organoids) from the menstrual cup samples and from biopsy samples?\n\nWhat Will Happen in the Study:\n\n* Participants will use a menstrual cup at home to collect menstrual blood.\n* They will also have a standard endometrial biopsy done by a healthcare provider.\n* After both collections, participants will fill out a short survey about how comfortable and easy it was to use the menstrual cup.\n\nWhat the Study Will Measure:\n\n* Feasibility: How well participants are able to use the menstrual cup and send in the sample.\n* Sample Quality: Whether the menstrual cup collects enough good-quality tissue for testing, and how it compares to biopsy samples.\n* Participant Experience: How women feel about using the menstrual cup, based on the survey.\n* Lab Testing: Whether researchers can successfully grow endometrial organoids from both types of samples.\n\nWhy This Study Matters: If this method works, it could offer a gentler, more convenient way for women to get checked for endometrial cancer-especially those who need regular screening. It could also make it easier to collect samples for research and improve early detection of cancer.",[73,45,117,241],"Early Detection of Cancer",[73,45,117,243,244],"Early detection","Organoids","2026-06-09",{"date":247,"type":92},"2026-06-10",{"date":249,"type":92},"2025-11-20",{"date":251,"type":23},"2027-03",{"name":253,"class":99},"Jessica D. St. Laurent, MD",{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":18,"minAge":108,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":111,"phases":262,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":129},"100470888","phase-2-a-phase-iia-randomized-double-blinded-clinical-trial-of-naproxen-or-aspirin-for-cancer-immune-interception-in-lynch-syndrome-100470888","NCT05411718","A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome","Inclusion Criteria:\n\n* Participants must have Lynch syndrome defined as meeting any of the following:\n\n  1. \"Mutation-Positive Lynch syndrome\": carriers or obligate carriers (by pedigree) of a pathogenic mutation in one of the DNA mismatch repair (MMR) genes (i.e., MLH1, MSH2\u002FEPCAM, MSH6, or PMS2).\n  2. \"Mutation-Negative Lynch syndrome\": patients with a personal history of a non-sporadic MMR deficient premalignant lesion (i.e., polyp) or a non-sporadic MMR deficient malignant tumor (where \"non-sporadic MMR deficient\" is defined by: microsatellite-instability high by either immunohistochemistry or MSI testing or both, but no evidence of MLH1 promoter methylation in cases with loss of both MLH1 and PMS2, and\u002For no evidence of BRAF mutation in cases with loss of both MLH1 and PMS2) but germline MMR genetic testing showed either a variant of unknown significance or mutation negative result or had declined germline MMR genetic test-ing.\n* Participants must not have evidence of active\u002Frecurrent malignant disease for 6 months.\n* Participants must be at least 6 months from any prior cancer-directed treatment (such as surgical resection, chemotherapy, immunotherapy, hormonal therapy or radiation).\n* Participants must have endoscopically accessible distal colon and\u002For rectal mucosa (i.e., partici-pants must have at least part of the descending\u002Fsigmoid colon and\u002For rectum intact).\n* Participants must consent to one standard of care lower GI endoscopy (flexible sigmoidoscopy or colonoscopy) with biopsies and one flexible sigmoidoscopy with biopsies that will be 12 months (+14 days) apart.\n* Participants must consent to refrain from using aspirin or NSAIDs or COX-inhibitors for the du-ration of the trial\n* Age ≥18 years. Because no dosing or adverse event data are currently available on the long-term use of naproxen or aspirin in patients \\\u003C18 years of age, children are excluded from this study but will be eligible for future pediatric trials, if applicable.\n* ECOG performance status ≤1 OR Karnofsky ≥70%; see Appendix A.\n* Participants must have normal organ and marrow function as defined below:\n\nHemoglobin \\>10 g\u002FdL or Hematocrit \\> 30 % Leukocyte count ≥3,000\u002Fmicroliter Platelet count ≥100,000\u002Fmicroliter Absolute neutrophil count ≥1,500\u002Fmicroliter Creatinine ≤1.5 x institutional ULN (OR GFR \\>30ml\u002Fmin\u002F1.73m2) Total bilirubin ≤2 x institutional ULN AST (SGOT) ≤2.5 × institutional ULN ALT (SGPT) ≤2.5 × institutional ULN\n\n* The effects of naproxen on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because NSAIDs are known to be teratogenic, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation. Should a woman become pregnant or suspect she is pregnant at the time of study entry or while participating in this study, she should inform her study physician immediately. Women of childbearing potential must agree to base-line and pre-drug pregnancy tests.\n* Ability to understand and the willingness to sign a written informed consent document.\n* Willing and able to adhere to the prohibitions and restrictions specified in the final approved pro-tocol.\n* Willing to undergo yearly standard of care screening colonoscopy for the duration of the clinical trial.\n\nExclusion Criteria:\n\n* Individuals with presence of two somatic mutations\u002Floss of heterozygosity (LOH) in one of the four MMR genes (MLH1, MSH2, MSH6, and PMS2) in MMR-deficient neoplasm (defined as a tumor with MSI-H by PCR analysis or loss of staining in one of the four MMR proteins).\n* Individuals who received scheduled NSAIDs or COX-inhibitors of any kind for \\>3 days during anytime within the 2 weeks prior to baseline eligibility screening visit. By exception, individuals receiving cardio-protective aspirin (e.g., 81 mg PO daily) will be eligible provided they are will-ing to stop no less than 7 days prior to starting on naproxen or aspirin in this study.\n* Individuals who are status post total proctocolectomy (i.e., removal of all colon and rectum).\n* Individuals with active gastroduodenal ulcer disease in the preceding 5 years.\n* Individuals with any history of transfusion-dependent gastrointestinal bleeding, gastrointestinal perforation or gastrointestinal obstruction. If any of these events had been due to a malignancy of the GI tract and the malignancy has since been removed, the patient is eligible.\n* Individuals with history of myocardial infarction, stroke, coronary-artery bypass draft, invasive coronary revascularization in the preceding 5 years.\n* Individuals taking the drugs listed below may not be randomized unless they are willing to stop the medications (and possibly change to alternative non-excluded medications to treat the same conditions) no less than 7 days prior to starting naproxen or aspirin on this study. Consultation with the participant's primary care provider may be obtained but is not required. The use of the following drugs or drug classes is prohibited during naproxen\u002Faspirin treatment:\n\n  * Investigational agents;\n  * NSAIDs: such as ketorolac, sulindac, ibuprofen, and others;\n  * COX-2 inhibitors: such as Celecoxib, Rofecoxib and other COX-2;\n  * Antiplatelet agents: such as aspirin, clopidogrel, ticlopidine, dipyridamole, abciximab, tirofi-ban, eptifibatide and prasugrel;\n  * Anticoagulants:\n\n    * Heparin;\n    * Heparinoids: such as fondaparinux, danaparoid and other heparinoids;\n    * Low-molecular weight heparins: such as enoxaparin, dalteparin, parnaparin, reviparin, tinzaparin, ardeparin, certoparin, lepidurin, bivalidurin;\n    * Other anticoagulants: argatroban, apixaban, dabigatran, rivaroxaban, warfarin, aceno-coumarol, dicumarol, phenindione and other anticoagulants;\n  * Lithium;\n  * Selective serotonin and norepinephrine reuptake inhibitors: minalcipran, fluoxetine, paroxe-tine, nefazadine, citalopram, clovoxamine, escitalopram, flesinoxan, femoxitene, duloxetine, venlafaxine, vilazodone, sibutramine, desvenlafaxine;\n  * Anticonvulsants: phenytoin, parakdehyde, valproic acid, carbamazepine, trimethadione, phenobarbital, diazepam, chlormethiazole, mephenytoin, ethotoin, paramethadione, phenac-emide, mephobarbital, oxcarbazepine, zonisamide, piracetam, vigabatrin, felbamate, gabapentin, beclamide, phosphenytoin, stripentol, tiagabine, topiramate, pregabalin, lacosa-mide, rufinamide, caramiphen;\n  * Antibiotics and antifungals:\n\n    o Fluorquinolones: such as ofloxacin, norfloxacin, levofloxacin;\n  * Other agents: teriflunomide, cyclosporine, tacrolimus, ginkgo, gossypol, meadowsweet, fe-verfew, beta glucan, pentosan, pentoxifylline, cilostazol, erlotinib, pemetrexed, methotrex-ate, pralatrexate.\n* Individuals with uncontrolled renal insufficiency or renal failure.\n* History of allergic reactions attributed to naproxen or aspirin.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, uncon-trolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac ar-rhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study require-ments.\n* Pregnant, breast-feeding, or women of childbearing potential unwilling to use a reliable contra-ceptive method. Pregnant women are excluded from this study because Naproxen\u002FNSAIDs is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with naproxen or aspirin, breastfeeding should be discontinued if the mother is treated with naproxen.\n\nInclusion of Women and Minorities:\n\n-Participants will be adult men and women of all races and ethnic groups, who are at least 18 years old, and who are deemed eligible for this trial. Children will not be recruited to the trial.\n\nOur minority recruitment strategies will include identifying participants through the University of Texas MD Anderson Cancer Center Familial High-Risk Gastrointestinal Cancer Clinic and Weill Cornell Med-ical College. We will advertise the study on minority and other national websites.",{"count":261,"type":23},40,[263],"PHASE2","To learn about the effects of naproxen and aspirin on the normal colon in people with Lynch Syndrome.",[266,267,45],"T Cells","Colorectal Cancer","2026-05-28",{"date":270,"type":92},"2026-06-01",{"date":272,"type":92},"2023-03-21",{"date":274,"type":23},"2026-11-30",{"name":276,"class":99},"M.D. Anderson Cancer Center",{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":18,"minAge":108,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":298},"100470831","collecting-blood-and-stool-samples-to-detect-colorectal-cancer-or-advanced-neoplasia-in-lynch-syndrome-patients-100470831","NCT05410977","Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients","Detection of Colorectal Cancer or Advanced Neoplasia by Stool DNA in Lynch Syndrome: CORAL Study","Inclusion Criteria:\n\n* Patients at least 18 years of age\n* Individuals diagnosed with Lynch syndrome (mutation in MLH1, MSH2, MSH6, PMS2, EPCAM) or colorectal cancer (CRC) with suspected Lynch syndrome or individuals diagnosed with early onset CRC (\\\u003C55 years old)\n* Colonoscopy\u002Fflexible sigmoidoscopy (flex sig) scheduled +\u002F- 90 days from sample collection\n* Patient has agreed to participate and has signed the study consent form\n\nExclusion Criteria:\n\n* Patient has known cancer (stage I-IV) within 5 years prior to current sample collection (not including basal cell or squamous cell skin cancers; if patient has not been seen or if information is not available, the patient is eligible)\n* Patient has received chemotherapy class drugs for the treatment of cancer in the 5 years prior to current sample collection\n* Patient has had any abdominal radiation therapy prior to current sample collection\n* Patient had therapy to the target (non-hyperplastic) lesion with intent to completely remove or debulk the lesion prior to sample collection \\[examples include snare polypectomy, endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), surgical resection, trans anal excision\\]\n* Patient has prior diagnosis of non-lynch hereditary colon cancer syndrome \\[familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), Peutz-Jeghers syndrome (PJS), juvenile polyposis syndrome (JPS), PTEN, POL\\]\n* ADDITIONAL STOOL EXCLUSIONS:\n* Bowel prep \\\u003C7 days prior to stool collection\n* Oral or rectal contrast given within 7 days prior to stool collection\n* Presence of ileostomy\n* Enteral feeds or total parenteral nutrition (TPN)\n* Diagnosis of inflammatory bowel disease",{"count":285,"type":23},950,"This study collects blood and stool samples from patients with suspected or diagnosed Lynch syndrome to evaluate a deoxyribonucleic acid (DNA) screening technique for the detection of colorectal cancer in Lynch syndrome patients.",[288,45],"Colorectal Carcinoma","2026-05-22",{"date":291,"type":92},"2026-05-27",{"date":293,"type":92},"2022-03-30",{"date":295,"type":23},"2027-12-31",{"name":297,"class":99},"Mayo Clinic",9,{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":18,"minAge":307,"maxAge":308,"enrollmentInfo":309,"targetDuration":4,"studyType":111,"phases":311,"briefSummary":313,"conditions":314,"keywords":315,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":129},"100637101","phase-3-preventive-dendritic-cell-vaccination-for-lynch-syndrome-carriers-100637101","NCT07609901","Preventive Dendritic Cell Vaccination for Lynch Syndrome Carriers","Prevention of Tumour Occurrence by Targeting Emergent Cancer Neoantigens Through Therapeutic Vaccination in Lynch Syndrome Carriers: a Phase III Clinical Trial.","PROTECT-Lynch","Inclusion Criteria:\n\n* a confirmed gPV in MLH1 or MSH2 and without a prior history of MMR-D cancer.\n* a confirmed gPV in MSH6, whether or not they have a history of MMR-D cancer. MSH6 subjects with a history of MMR-D cancer have to be cancer-free for more than 1 year.\n* previous surgical treatment may include any resection up to and including hemicolectomy; subjects who have undergone (sub)total colectomy are excluded due to the substantially reduced risk of cancer occurrence.\n* aged between 35 and 75 for subjects with gPV in MLH1 and MSH2; and aged between 40 and 75 for subjects with gPV in MSH6.\n* Lynch syndrome subjects without clinical signs of disease.\n* Lynch syndrome subjects without prior treatment for LS-associated cancer, except for MSH6 subjects who are \\>1 year disease-free and whose prior surgical treatment did not include subtotal colectomy.\n* Routine surveillance colonoscopy must be performed within 16 weeks prior to start of study, to exclude (pre)malignancy.\n* HLA-A02.01 genotype\n* Adequate hematologic, renal, and liver function as defined by laboratory values: WBC \\>3.0\\^109\u002Fl, lymphocytes \\>0.8\\^109\u002Fl, platelets \\>100\\^109\u002Fl, haemoglobin \\>7,0 mmol\u002Fl (9.0 g\u002Fdl), estimated glomerular filtration rate \\> 45 ml\u002Fmin\u002F1.73m2, AST\u002FALT \\\u003C3 x ULN, serum crea¬tinine \\\u003C150 µmol\u002Fl, serum bilirubin \\\u003C1.5 x ULN (exception: Gilbert's syndrome is permitted).\n* WHO performance status of 0 or 1\n* No concomitant use of immunosuppressive drugs orally or intravenously. Topical and intranasal steroids are permitted.\n* No uncontrolled infectious disease, i.e., negative testing for HIV, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and syphilis (Treponema Pallidum Hemagglutination Assay (TPHA)).\n* No autoimmune disease such as, but not limited to, inflammatory bowel disease, multiple sclerosis, and lupus. Subjects with type 1 diabetes mellitus, hypothyroidism after autoimmune thyroiditis and skin disorders are not excluded.\n* No serious (bleeding and clotting) condition that may interfere with safe leukapheresis.\n* No pregnant or lactating women. hCG tests will be performed regularly during the trial to confirm absence of pregnancy.\n* No Women Of Child-Bearing Potential (WOCBP) or male partners of WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for up to 8 weeks after the last administration of the treatment. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal \\[defined as amenorrhea \\> 12 consecutive months\\].\n* Subjects must have absence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions must be discussed with the subject before registration in the trial.\n* Expected adequacy of follow-up.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Individuals with a history of malignancy in the past. Allowed malignancies are adequately treated basal cell carcinoma and squamous cell carcinoma of the skin, carcinoma in situ (e.g., DCIS\u002FLCIS\u002Fcervical CIS), papillary thyroid carcinoma, and low-risk prostate carcinoma; all locally resected with negative surgical margins and not treated with systemic therapy.\n* Organ allografts.\n* Known allergy to shellfish.\n* Inability to understand and communicate in Dutch.","35 Years","75 Years",{"count":310,"type":23},372,[312],"PHASE3","The primary objective is to assess the effect of vaccination with neopeptide-loaded dendritic cells on disease-free survival (DFS) compared to placebo in LS subjects who are known to be carrier of a germline MMR-gene mutation with no signs of disease.",[45],[316,317,318,45,319,320],"Dendritic Cells","Cancer Vaccine","Hereditary Cancer","Prevention","Neoantigens","2026-05-20",{"date":291,"type":92},{"date":324,"type":23},"2026-10-01",{"date":326,"type":23},"2032-10-01",{"name":328,"class":99},"Radboud University Medical Center",{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":17,"sex":18,"minAge":108,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":111,"phases":337,"briefSummary":338,"conditions":339,"keywords":4,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":347,"leadSponsor":349,"locationsCount":129},"100634647","a-web-based-program-kindred-to-improve-the-understanding-of-genetic-cancer-risk-and-cancer-genetic-testing-in-african-american-families-100634647","NCT07542405","A Web-Based Program (Kindred) to Improve the Understanding of Genetic Cancer Risk and Cancer Genetic Testing in African American Families","Kindred: Family Centered Approaches to Promoting Cascade Screening for Hereditary Cancer Syndromes Among African Americans","Inclusion Criteria:\n\n* PROBANDS: Evaluation in the past one-year at the Breast and Ovarian Cancer Risk Evaluation Clinic (BOCRE) or Cancer Genetics Clinic, both located at the University of Michigan (U-M) Rogel Cancer Center who are positive for hereditary breast and ovarian cancer syndrome (HBOC) (BRCA1, BRCA2) or Lynch Syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM); indeterminate negative; or variants of uncertain clinical significance (VUS). If more than one biological relative is known to have received an evaluation for and or completed germline testing for cancer risk, the relative who was evaluated the longest time ago to align with the tradition definition of a proband as defined by the National Cancer Institute (NCI), i.e., the first person identified as possibility having a genetic disorder and who may receive counseling or testing\n* PROBANDS: \\>= 18-years-old\n* PROBANDS: Completed genetic testing for hereditary cancer syndromes, regardless of results\n* PROBANDS: Able to speak and read English\n* PROBANDS: Access to the internet\n* PROBANDS: Identifies as African American or Black (may have additional race or ethnicity identities)\n* RELATIVES: Biological relative of enrolled proband, regardless of testing completion or timing of testing\n* RELATIVES: \\>= 18 years old\n* RELATIVES: Able to speak and read English\n* RELATIVES: Access to the internet\n\nExclusion Criteria:\n\n* PROBANDS: No evaluation at U-M or other facility, or evaluation was more than one year ago, or received an evaluation more recently than the relative\n* PROBANDS: Under 18-years-old\n* PROBANDS: Did not receive cancer genetic testing\n* PROBANDS: Does not speak or read English\n* PROBANDS: Does not have internet access\n* PROBANDS: Does not identify as African American or Black\n* RELATIVES: Not a biological relative of proband\n* RELATIVES: Under 18-years-old\n* RELATIVES: Does not speak or read English\n* RELATIVES: Does not have internet access",{"count":138,"type":23},[113],"This clinical trial studies whether a web-based program, Kindred, works to improve the understanding of genetic cancer risk and cancer genetic testing in African American families. Between 5% and 10% of all cancers are caused by genetic changes that are hereditary, which means that they run in families. Some kinds of cancer or a family history of cancer means individuals are more likely to have a genetic change. If a genetic change is identified in a family, other relatives can choose to undergo hereditary cancer genetic testing to better understand their cancer risk. In families where a genetic change is not identified, or results are uncertain, relatives may also benefit from discussing their cancer risk with providers and, in some cases, getting hereditary cancer genetic testing themselves. Research has shown that African Americans are less likely than other racial groups to engage in cancer genetic testing. Kindred is an online tool that provides information so individuals can learn about their cancer genetic test results, how cancer genetic testing can help individuals and families understand their overall cancer risk (and strategies for reducing risk), and ways to talk with each other about cancer risk and health. This may be an effective way to improve the understanding of genetic cancer risk and cancer genetic testing in African American families.",[340,341,342,45],"BRCA1-Related Hereditary Breast and Ovarian Cancer Syndrome","BRCA2-Related Hereditary Breast and Ovarian Cancer Syndrome","Hereditary Neoplastic Syndrome","2026-05-18",{"date":345,"type":92},"2026-05-19",{"date":220,"type":23},{"date":348,"type":23},"2028-06",{"name":350,"class":99},"University of Michigan Rogel Cancer Center",{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":12,"sex":18,"minAge":108,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":363,"startDateStruct":364,"completionDateStruct":365,"leadSponsor":367,"locationsCount":129},"100637477","periodontal-disease-in-patients-with-lynch-syndrome-100637477","NCT07600710","Periodontal Disease in Patients With Lynch Syndrome","Periodontal Disease in Patients With Lynch Syndrome: a Retrospective Observational, Monocentric Case-control Study","SMILy_25","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. All sexes eligible\n3. Established diagnosis of LS performed as part of clinical practice, with a germline pathogenic\u002Flikely pathogenic variant in one of the following genes: MLH1, MSH2, MSH6, PMS2, and EpCAM\n4. LS subjects undergoing surveillance gastrointestinal endoscopy according to clinical practice and international guidelines.\n5. Subjects underwent dental and periodontal examination\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years;\n2. Absence of sufficient periodontal clinical or radiographic data to establish a periodontal diagnosis;\n3. Subjects affected by systemic, autoimmune, chronic inflammatory, neurological, or severe psychiatric disorders, or by any other clinical condition that may interfere with study participation or data interpretation\n4. Subjects with systemic conditions known to strongly affect periodontal status (e.g. uncontrolled diabetes, autoimmune inflammatory diseases, ongoing cancer therapy) were excluded to reduce major confounding factors that could independently alter periodontal outcomes.",{"count":7,"type":23},"The field of human microbiome research has undergone a revolution in its approach toward understanding how microorganisms influence the physiology of their host 1. The influence of the oral microbiota is not confined to this location 2. Periodontitis is a \"chronic inflammatory disease associated with dysbiotic plaque biofilms and characterized by a progressive destruction of the tooth supporting apparatus\"3. Given these observations, the central research question of the present study is to determine the prevalence of periodontitis in patients with Lynch syndrome (LS) compared with reference prevalence estimates from the general population40.",[45,362],"Periodontal Disease",{"date":289,"type":92},{"date":270,"type":23},{"date":366,"type":23},"2026-07-31",{"name":368,"class":99},"Rotundo Roberto",{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":373,"acronym":374,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":18,"minAge":108,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":378,"conditions":379,"keywords":380,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":298},"100295306","cascade-genetic-testing-for-hereditary-breastovarian-cancer-and-lynch-syndrome-in-switzerland-100295306","NCT03124212","Cascade Genetic Testing for Hereditary Breast\u002FOvarian Cancer and Lynch Syndrome in Switzerland","CASCADE","Inclusion Criteria:\n\n1. Carrier of a mutation associated with HBOC or LS\n2. Have at least one living blood relative\n3. Men and women\n4. 18 years old and older\n5. Mentally and physically able to provide informed consent\n6. Can read and speak German or French or Italian or English\n7. Currently living in Switzerland.\n\nExclusion Criteria:\n\n1. Carriers of unclassified variants (VUS) in BRCA1, BRCA2 or MLH1, MSH2, MSH6, PMS2, EPCAM genes\n2. Not living in Switzerland\n3. Patients who are critically ill and cannot complete the CASCADE survey\n4. Participants who are institutionalized (e.g., nursing homes) or incarcerated",{"count":377,"type":23},700,"Breast, colorectal, ovarian, and endometrial cancers constitute approximately 30% of newly diagnosed cancer cases in Switzerland and affect more than 12,000 individuals annually. Several hundred of these patients are likely to carry known genetic mutations associated with HBOC or LS. Genetic testing for hereditary susceptibility to cancer can prevent many cancer deaths through early identification and engagement in high-risk management care that involves intensive surveillance, chemoprevention and\u002For prophylactic surgery. However, current rates of genetic testing indicate that many Swiss mutation carriers and their family members do not use cancer genetic services (counseling and\u002For testing), either due to lack of coordination of care or due to lack of communication about the mutation among family members.\n\nCascade screening identifies and tests family members of a known mutation carrier. It determines whether asymptomatic family members are carriers of the identified mutation and proposes management options to reduce harmful outcomes. Robust evidence of basic science and descriptive population-based studies in Switzerland support the necessity of cascade screening for HBOC and LS. However, translation of this knowledge into public health interventions is lacking.\n\nSpecific Aims of the CASCADE study are:\n\n1. Survey Index Patients diagnosed with HBOC or LS from clinic-based genetic testing records and determine their cancer status and surveillance practices; needs for coordination of medical care; psychosocial needs; patient-provider and patient-family communication needs; quality of life; willingness to serve as advocates for cancer genetic services for blood relatives.\n2. Survey first- and second-degree relatives, and first cousins identified from pedigrees and\u002For family history records of HBOC and LS Index Patients and determine their cancer and mutation status; cancer surveillance practices; needs for coordination of medical care; barriers and facilitators to using cancer genetic services; psychosocial needs; patient-provider and patient-family communication needs; quality of life; willingness to participate in a study designed to increase use of cancer genetic services.\n3. Explore the influence of patient-provider communication about genetic cancer risk on patient-family communication and the acceptability of a family-based communication, coping, and decision support intervention with focus group(s) of mutation carriers and blood relatives.",[185,45],[381,382,383,384],"mutation carrier","blood relative","genetic testing","family-based cohort","2026-05-10",{"date":387,"type":92},"2026-05-13",{"date":389,"type":92},"2017-04-01",{"date":391,"type":23},"2035-01-31",{"name":393,"class":99},"University of Basel",{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":18,"minAge":108,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":111,"phases":404,"briefSummary":405,"conditions":406,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":419},"100626490","impact-of-consumption-of-ultra-processed-foods-in-individuals-at-high-risk-of-cancer-100626490","NCT07436312","Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer","Impact of a Mixed Intervention Aiming to Decrease the Consumption of Ultra-processed Foods on the Global Diet Quality in Individuals at High Risk of Cancer","U-TRANS","Inclusion Criteria:\n\n1. Age \\> 18 years,\n2. Individuals at increased risk of different cancers as defined within the Interception program,\n3. With a baseline WCRF score ≤ 5 at entry in the Interception program,\n4. Agreeing to participate and who have given their written agreement for the study,\n5. Agreeing to fill in the questionnaires on the dedicated platform for the duration of the study,\n6. Participant have and accept to use their smartphone,\n7. All participants must understand spoken and written French language\n\nExclusion Criteria:\n\n1. Psychiatric disorders or cognitive impairments precluding participation,\n2. Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent.",{"count":403,"type":23},170,[113],"The U-TRANS study was initiated by Gustave Roussy, which is its sponsor\\*. It is part of the Interception Program and aims to reduce the consumption of ultra-processed foods in order to improve the overall quality of the diet among people at high risk of cancer (WCRF score ≤ 5, corresponding to low adherence to nutritional cancer prevention recommendations: eating a diet rich in whole grains, vegetables, fruit and fibre, and limiting ultra-processed foods, red meat, processed meats, sugary drinks and alcohol). It assesses the impact of a digital intervention (based on the use of the Open Food Facts app) as a complement to the nutritional education provided by the Interception program.",[66,407,33,45,408,409],"Pancreas Cancer","Germline BRCA1 Gene Mutation","Germline BRCA2 Gene Mutation","2026-05-05",{"date":412,"type":92},"2026-05-08",{"date":414,"type":92},"2026-05-04",{"date":416,"type":23},"2028-03",{"name":418,"class":99},"Gustave Roussy, Cancer Campus, Grand Paris",3,{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":426,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":18,"minAge":307,"maxAge":308,"enrollmentInfo":428,"targetDuration":4,"studyType":111,"phases":430,"briefSummary":432,"conditions":433,"keywords":434,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":129},"100624635","phase-1-preventive-dendritic-cell-vaccination-for-lynch-syndrome-100624635","NCT07412197","Preventive Dendritic Cell Vaccination for Lynch Syndrome","Targeting Cancer Neoantigens Through Multi-Epitope Vaccination for Tumour Prevention in Lynch Syndrome: a Phase I\u002FII Clinical Trial.","PREVENT-Lynch","Inclusion Criteria:\n\n* a confirmed gPV in MLH1 or MSH2 and without a prior history of MMR-D cancer.\n* a confirmed gPV in MSH6, whether or not they have a history of MMR-D cancer. MSH6 subjects with a history of MMR-D cancer have to be cancer-free for more than 1 year.\n* previous surgical treatment may include any resection up to and including hemicolectomy; subjects who have undergone (sub)total colectomy are excluded due to the substantially reduced risk of cancer occurrence.\n* aged between 35 and 75 for subjects with gPV in MLH1 and MSH2; and aged between 40 and 75 for subjects with gPV in MSH6.\n* Lynch syndrome subjects without clinical signs of disease.\n* Lynch syndrome subjects with a prior history of colorectal premalignancies with at least 1 adenoma sample archived.\n* Lynch syndrome subjects without prior treatment for LS-associated cancer, except for MSH6 subjects who are \\>1 year disease-free and whose prior surgical treatment did not include subtotal colectomy.\n* Routine surveillance colonoscopy must be performed within 16 weeks prior to start of study, to exclude (pre)malignancy.\n* HLA-A02.01 genotype\n* Adequate hematologic, renal, and liver function as defined by laboratory values: WBC \\>3.0\\^109\u002Fl, lymphocytes \\>0.8\\^109\u002Fl, platelets \\>100\\^109\u002Fl, haemoglobin \\>7,0 mmol\u002Fl (9.0 g\u002Fdl), estimated glomerular filtration rate \\> 45 ml\u002Fmin\u002F1.73m2, AST\u002FALT \\\u003C3 x ULN, serum crea¬tinine \\\u003C150 µmol\u002Fl, serum bilirubin \\\u003C1.5 x ULN (exception: Gilbert's syndrome is permitted).\n* WHO performance status of 0 or 1\n* No concomitant use of immunosuppressive drugs orally or intravenously. Topical and intranasal steroids are permitted.\n* No uncontrolled infectious disease, i.e., negative testing for HIV, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and syphilis (Treponema Pallidum Hemagglutination Assay (TPHA)).\n* No autoimmune disease such as, but not limited to, inflammatory bowel disease, multiple sclerosis, and lupus. Subjects with type 1 diabetes mellitus, hypothyroidism after autoimmune thyroiditis and skin disorders are not excluded.\n* No serious (bleeding and clotting) condition that may interfere with safe leukapheresis.\n* No pregnant or lactating women. hCG tests will be performed regularly during the trial to confirm absence of pregnancy.\n* No Women Of Child-Bearing Potential (WOCBP) or male partners of WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for up to 8 weeks after the last administration of the treatment. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal \\[defined as amenorrhea \\> 12 consecutive months\\].\n* Subjects must have absence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions must be discussed with the subject before registration in the trial.\n* Expected adequacy of follow-up.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Individuals with a history of malignancy in the past. Allowed malignancies are adequately treated basal cell carcinoma and squamous cell carcinoma of the skin, carcinoma in situ (e.g., DCIS\u002FLCIS\u002Fcervical CIS), papillary thyroid carcinoma, and low-risk prostate carcinoma; all locally resected with negative surgical margins and not treated with systemic therapy.\n* Organ allografts.\n* Known allergy to shellfish.\n* Inability to understand and communicate in Dutch.",{"count":429,"type":23},13,[431,263],"PHASE1","The aim of this study is to assess safety, feasibility and immunogenicity of vaccination with neopeptide-loaded dendritic cells in Lynch Syndrome subjects who are known to be carrier of a germline MMR-gene mutation without signs of disease.",[45],[435,436,437,45,319,320],"Dendritic cells","Cancer vaccine","Hereditary cancer","2026-04-30",{"date":440,"type":92},"2026-05-06",{"date":442,"type":23},"2026-08",{"date":444,"type":23},"2036-06",{"name":328,"class":99},{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":450,"acronym":451,"eligibilityCriteria":452,"healthyVolunteers":12,"sex":18,"minAge":108,"maxAge":453,"enrollmentInfo":454,"targetDuration":456,"studyType":25,"phases":4,"briefSummary":457,"conditions":458,"keywords":459,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":129},"100627222","evaluation-of-capsule-colonoscopy-in-patients-with-lynch-syndrome-100627222","NCT07445828","Evaluation of Capsule Colonoscopy in Patients With Lynch Syndrome","Lynch syndrome","Inclusion Criteria:\n\n* Genetically confirmed Lynch syndrome with a planned surveillance colonoscopy according to guideline-based recommendations\n* Age 18-60 years\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Need for an translator\n* Known history of gastroparesis or intestinal pseudo-obstruction\n* Known or suspected stricture or stenosis of the gastrointestinal tract\n* Previous small bowel or colonic resection\n* Dysphagia or swallowing difficulties\n* Severe debilitating disease\n* Allergy or contraindication to any medications or products used in the study\n* Pregnancy or breastfeeding","60 Years",{"count":455,"type":23},78,"6 Months","Lynch syndrome is the most common hereditary cancer syndrome and is caused by pathogenic variants in DNA mismatch repair genes, resulting in a markedly increased lifetime risk of colorectal cancer. The estimated lifetime risk of colorectal cancer varies by the affected gene and is approximately 54-74% in men and 30-52% in women with Lynch syndrome. Colorectal cancer in this population is typically diagnosed at a younger age than in the general population. Current national guidelines recommend colonoscopic surveillance every one to two years beginning at 20-25 years of age to reduce colorectal cancer risk. However, individualized modification of surveillance strategies is under active consideration based on factors such as the specific mutated gene, family history of cancer, smoking status, prior malignancies, and age at surveillance initiation.\n\nConventional colonoscopy, the current standard method for colorectal evaluation, may cause substantial discomfort or anxiety, leading some patients to decline participation. Colonoscopy is also resource intensive, and procedural capacity is limited. Previously reported limitations in colonoscopy resources and quality in Sweden highlight the need to evaluate alternative surveillance and screening approaches.\n\nColon capsule endoscopy (CCE) has been available for clinical use since 2006 as a non-invasive alternative to colonoscopy, enabling endoscopic visualization of the entire colon. The system consists of a single-use, swallowable capsule containing miniature cameras that capture images as the capsule progresses through the gastrointestinal tract via natural peristalsis. Images are transmitted wirelessly to a portable data recorder worn by the patient and subsequently reviewed using dedicated software.\n\nCCE offers several advantages compared with conventional colonoscopy and CT colonography, including no requirement for sedation, endoscope insertion, gas insufflation, or ionizing radiation. The examination and image acquisition can be performed outside the hospital setting. This patient-centered approach has the potential to improve adherence to repeated examinations and long-term surveillance programs, which is particularly important for individuals with hereditary colorectal cancer syndromes. CCE may also reduce demands on healthcare resources.\n\nInternational guidelines indicate that the mucosal diagnostic performance of CCE is comparable to that of standard colonoscopy and that the method is appropriate for screening purposes. Adequate bowel preparation is required for both colonoscopy and CCE. Unlike conventional colonoscopy, bowel cleansing cannot be optimized during CCE, and the procedure is limited by capsule battery life, typically 10-12 hours. To maintain bowel cleanliness and facilitate capsule transit, patients administer laxative and prokinetic agents at predefined time points during the examination.\n\nThe primary objective of this study is to evaluate the diagnostic performance and safety of colon capsule endoscopy as a first-line surveillance modality in patients with Lynch syndrome and to assess patient experience and acceptance of CCE compared with conventional colonoscopy.",[45],[45,460],"caspule colonoscopy","2026-04-29",{"date":438,"type":92},{"date":464,"type":23},"2026-05",{"date":466,"type":23},"2029-12-31",{"name":468,"class":99},"Region Skane",{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":475,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":18,"minAge":108,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":479,"conditions":480,"keywords":501,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":530},"100570529","lynch-syndrome-x-talk-of-enteral-mucosa-with-immune-system-100570529","NCT06708429","Lynch Syndrome X-Talk of Enteral Mucosa With Immune System","Impact of Immune-surveillance on the Development of Colorectal Cancer in Patients With Lynch Syndrome","LYNX-EYE","Inclusion Criteria (for participants with Lynch syndrome):\n\n* Age ≥18 years\n* All sexes eligible\n* Established diagnosis of Lynch syndrome performed as part of clinical practice, with a germline pathogenic\u002Flikely pathogenic variant in one of the following genes: MLH1, MSH2, MSH6, PMS2, and EpCAM\n* Subjects with Lynch syndrome undergoing surveillance gastrointestinal endoscopy and\u002For surgery according to clinical practice\n* Fertile patients (both males and females) are eligible\n* Lactating women are eligible\n\nInclusion Criteria (for participants without Lynch syndrome):\n\n* Age ≥18 years\n* All sexes eligible\n* Patients with sporadic colorectal lesions, including colorectal cancer and colorectal adenomas\n* Healthy controls without colorectal cancer or adenomas undergoing lower gastrointestinal endoscopy for abdominal pain\n* PREMM5 \\\u003C 2.5 \\[PREMM5 is an online, free-to-use, clinical prediction algorithm that estimates the cumulative probability of an individual carrying a germline mutation in the mismatch repair genes responsible for Lynch syndrome\\].\n\nExclusion Criteria (for participants with or without Lynch syndrome):\n\n* Age \\\u003C 18 years;\n* Diseases that are known to predispose to colorectal cancer (personal past or recent history of inflammatory bowel disease);\n* Patients unable\u002Funwilling to provide consent;\n* Pregnancy",{"count":478,"type":23},300,"Lynch syndrome (OMIM #120435) is the most common dominantly inherited colorectal cancer syndrome with an estimated prevalence of 1:270 individuals. It increases the lifetime risk of colorectal and endometrial cancer primarily, but it is associated with a high risk of other cancers (pancreas, stomach, ovarian, central nervous system, skin, among others). It is caused by a germline mutation in one of four DNA mismatch repair genes or a terminal deletion of the MSH2-adjacent gene EpCAM.\n\nDespite adherence to cancer surveillance programs, many patients still develop colorectal cancer and endometrial cancer. The Prospective Lynch Syndrome Database (PLSD) suggests that more frequent surveillance intervals do not significantly improve cancer risk reduction. The PLSD also revealed that the incidence of colorectal cancer in MLH1 and MSH2 carriers was even higher than previously expected, reaching as high as 41-36% among MLH1 carriers, regardless of ethnic background. The development of colorectal cancer despite surveillance is an unresolved question. Therefore, there is an unmet need for effective cancer prevention strategies.",[45,481,482,483,484,485,486,318,487,488,489,490,491,492,493,494,495,496,497,498,499,500],"Lynch Syndrome I","Lynch Syndrome II","Lynch Syndrome I (Site-specific Colonic Cancer)","HNPCC","HNPCC Gene Mutation","Hereditary Cancer Syndrome","MLH1 Gene Mutation","MLH1 Gene Deletion+Duplication","MLH1 Loss of Expression","MLH1 Gene Inactivation","MSH2 Gene Mutation","MSH2 Gene Deletion+Duplication","MSH2 Loss of Expression","MSH2 Gene Inactivation","MSH6 Gene Mutation","MSH6 Loss of Expression","MSH6 Gene Inactivation","PMS2 Gene Mutation","PMS2 Gene Inactivation","PMS2 Loss of Expression",[502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520],"Colorectal cancer","Endometrial cancer","Lynch syndrome-associated cancer","Surveillance","Cancer surveillance","Immune profile","Immune escape","Mismatch repair deficiency","Microbiota","Liquid biopsy","MicroRNA","Transcriptomic","Frame shift peptides","MLH1","MSH2","EpCAM","MSH6","PMS2","Hair matrix","2026-04-21",{"date":523,"type":92},"2026-04-24",{"date":525,"type":92},"2023-06-01",{"date":527,"type":23},"2034-06-01",{"name":529,"class":99},"San Raffaele University",5,{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":4,"eligibilityCriteria":537,"healthyVolunteers":17,"sex":18,"minAge":108,"maxAge":4,"enrollmentInfo":538,"targetDuration":4,"studyType":111,"phases":540,"briefSummary":541,"conditions":542,"keywords":544,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":552,"locationsCount":129},"100493350","videocapsule-endoscopy-in-lynch-syndrome-100493350","NCT05704010","Videocapsule Endoscopy in Lynch Syndrome","Role of Videocapsule Endoscopy in Lynch Syndrome: a Multicenter Italian Registry Study","Inclusion Criteria:\n\n* Pathogenic germline variant in one of the MMR genes (MLH1, MSH2\u002FEpcam, MSH6, or PMS2).\n\nExclusion Criteria:\n\n* Patients younger than 18 years of age\n* Patients unwilling or unable to provide informed consent\n* Patients with prior small bowel surgery\n* Patients with a contraindication to VCE",{"count":539,"type":23},100,[113],"Background Lynch syndrome is caused by a pathogenic variant in one of the four Mismatch Repair genes (MMR): MLH1, MSH2\u002FEpcam, MSH6, or PMS2. These pathogenic variants confer a higher risk of developing colorectal and other cancers, including small bowel cancer. The risk of developing a small bowel adenocarcinoma is about 100 times higher compared to individuals without Lynch syndrome, and the lifetime risk of small bowel cancer is estimated at 4,2%.\n\nThe diagnosis of a small bowel cancer depends on videocapsule endoscopy (VCE). This device is swalled so that it can record images of the small bowel, which are then stored on a wearable device for about 8 hours. The capsule is then expelled in the feces while the images are transferred to a computer to be analysed. To date, there is conflicting evidence on the efficacy of small bowel cancer screening with VCE\n\nRationale: this registry study will collect prospective data from patients with LS undergoing VCE\n\nAim: evaluate the incidence of neoplastic and pre-neoplastic lesions in patients with LS during a VCE-based small bowel cancer screening study\n\nDesign: this is a multicentric, observational study that analyzes data from diagnostic techniques already approved. Patients will not undergo diagnostic procedures beyond what would be recommended by clinical practice.",[45,481,482,487,491,495,498,543],"Small Bowel Adenocarcinoma",[545,546],"Videocapsule","Small bowel",{"date":548,"type":92},"2026-04-22",{"date":550,"type":92},"2018-11-01",{"date":466,"type":23},{"name":529,"class":99},{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":557,"acronym":558,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":18,"minAge":108,"maxAge":4,"enrollmentInfo":560,"targetDuration":4,"studyType":111,"phases":561,"briefSummary":562,"conditions":563,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":129},"100605506","phase-1-first-in-human-pilot-study-to-assess-the-safety-and-efficacy-of-dendritic-cells-loaded-with-frameshift-derived-neopeptides-for-the-prevention-of-cancer-in-of-lynch-syndrome-carriers-100605506","NCT07163403","First in Human Pilot Study to Assess the Safety and Efficacy of Dendritic Cells Loaded With Frameshift Derived Neopeptides for the Prevention of Cancer in of Lynch Syndrome Carriers","DELAY","Inclusion Criteria:\n\n1. Individuals that are carriers of a pathogenic or likely pathogenic germline variant in one of the mismatch repair genes (MLH1, MSH2, MSH6).\n2. Participants must have no evidence of active or previous invasive cancer.\n3. Participants must have endoscopically accessible colon.\n4. Participants must consent to follow the standard of care surveillance with colonoscopy and biopsies every 1-2 years.\n5. Age ≥ 18 years\n6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 (Karnofsky ≥70%).\n7. Haemoglobin ≥10 g\u002FdL or haematocrit ≥30%; Leukocyte count ≥3.0x109\u002Fl; Platelet count ≥100x109\u002Fl; Absolute neutrophil count ≥1.5x109\u002Fl; Absolut lymphocyte count ≥0.8x109\u002Fl.\n8. Creatinine clearance (calculated if measured is not available) ≥60mL\u002Fmin\u002F1.73m2.\n9. Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\]\u002Falanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\] ≤2 times the institutional upper limit of normal (ULN).\n10. Total bilirubin ≤ 1.5 the ULN; participants with Gilbert's disease may be enrolled with higher total bilirubin if their direct bilirubin is ≤1.5 times the ULN.\n11. Written informed consent.\n12. Women of child-bearing potential\\* must have a negative pregnancy test in serum before the inclusion in the study and agree to use highly effective contraceptive methods until one year following the las immunization dose. Highly effective contraceptive methods will include: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device, bilateral tubal occlusion, vasectomized partner and sexual abstinence. \\* A woman will be considered of childbearing potential, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as 0 menses for 12 months without an alternative medical cause. A high follicle stimulating hormone level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single follicle stimulating hormone measurement is insufficient.\n\nExclusion Criteria:\n\n1. Individuals that are carriers of a pathogenic or likely pathogenic germline variant in PMS2.\n2. Individuals with active malignancy or previous malignancy (excluding non-melanoma skin cancer)\n3. Participants who cannot be removed from their baseline medication for the duration of the trial to administer the investigational treatment. This includes the daily use of \\>100 mg aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase (COX) inhibitors.\n4. Any serious uncontrolled and \u002For unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with participant's safety, obtaining informed consent, or compliance to the study procedures.\n5. Patients with active systemic bacterial, viral or fungal infections or known to have human immunodeficiency virus (HIV) or to test positive for HIV antibody at screening.\n6. Positive hepatitis B surface antigen or hepatitis C antibody tests at screening.\n7. History of organ allograft or other history of immunodeficiency\n8. Individuals with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications.\n9. Pregnant or breastfeeding or planning to become pregnant during the first year after the completion of the study treatment.\n10. Men attempting or planning to conceive children during the first year after the completion of the study treatment.\n11. Participants cannot receive any other investigational agents in the last month before its inclusion.\n12. Participants unable to refrain to receive any type of vaccination during the first 12 weeks of the trial.\n13. Impossibility to proceed to the leukapheresis (e.g. absence of peripheral venous access).\n14. Any other problem that according to the investigator could interfere with the evaluation of the objectives",{"count":110,"type":23},[431],"Tha aim of this clinical trial is to evaluate safety and tolerability of autologous peripheral blood differentiated and matured adult dendritic cells. Immunogenicity of the prduct(DC-DELAY) will be evaluated also.",[45],"2026-04-10",{"date":566,"type":92},"2026-04-13",{"date":568,"type":92},"2025-09-04",{"date":570,"type":23},"2028-09-20",{"name":572,"class":99},"Fundacion Clinic per a la Recerca Biomédica",{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":578,"acronym":579,"eligibilityCriteria":580,"healthyVolunteers":12,"sex":18,"minAge":108,"maxAge":4,"enrollmentInfo":581,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":583,"conditions":584,"keywords":589,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":605,"locationsCount":129},"100629285","small-bowel-capsule-endoscopy-in-lynch-syndrome-100629285","NCT07472686","Small Bowel Capsule Endoscopy in Lynch Syndrome","Small Bowel Capsule Endoscopy for (Pre)Neoplastic Lesion Screening in Patients With Lynch Syndrome","iCARE4Lynch","Inclusion Criteria:\n\n* Patient carrying a pathogenic variant of the DNA mismatch repair gene (MMR) (MLH1, MSH2, MSH6, PMS2, EPCAM)\n* Capsule endoscopy screening for (pre)neoplastic lesions of the small intestine\n* No opposition to the reuse of healthcare data for research purposes\n\nExclusion Criteria:\n\n* Absence of documented MMR gene variant\n* Opposition to the study",{"count":582,"type":23},400,"The impact of small bowel (SB) capsule endoscopy (CE) on the screening (followed by diagnosis and treatment) of (pre)neoplastic lesions of the small bowel in Lynch syndrome (LS) patients is unknown.\n\nThe iCARE4Lynch study is a retrospective cohort of patients carrying a pathogenic variant of the DNA mismatch repair gene (MMR) (MLH1, MSH2, MSH6, PMS2, EPCAM) who had had at least one SBCE for screening of small bowel (pre)neoplastic lesions between January 1st 2000 and December 31 2024.",[585,586,587,45,588],"MMR Mutation","Small Bowel Adenoma","Small-bowel Adenocarcinoma","Cancer",[588,451,590,117,546,591,592,593,594,595,596,515,516,518,519,597],"Capsule endoscopy","Small-bowel adenoma","Small-bowel adenocarcinoma","Small-bowel cancer","Small-bowel capsule endoscopy","pathogenic variant","DNA mismatch repair gene (MMR)","EPCAM","2026-03-11",{"date":600,"type":92},"2026-03-16",{"date":602,"type":92},"2025-06-16",{"date":604,"type":23},"2026-12",{"name":606,"class":99},"Assistance Publique - Hôpitaux de Paris",{"id":608,"slug":609,"hasResults":12,"nctId":610,"briefTitle":611,"officialTitle":611,"acronym":612,"eligibilityCriteria":613,"healthyVolunteers":17,"sex":18,"minAge":108,"maxAge":4,"enrollmentInfo":614,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":616,"conditions":617,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":636},"100627590","liquid-biopsy-and-machine-learning-for-early-colorectal-cancer-adenomas-lynch-cancers-and-residual-disease-detection-100627590","NCT07450612","Liquid Biopsy and Machine Learning for Early Colorectal Cancer, Adenomas, Lynch Cancers, and Residual Disease Detection","BEACON","Inclusion Criteria:\n\n* All individuals included in the study need to have had a colonoscopy at the time of blood sampling.\n* Received standard diagnostic and staging (as necessary) procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.\n* Received standard pathological and endoscopic diagnosis and assessment for cohort assignment\n\nExclusion Criteria:\n\n* Lack of informed consent\n* Inflammatory bowel disease",{"count":615,"type":23},1200,"This is an multicenter study that will test the diagnostic accuracy of a blood test (i.e., a liquid biopsy) for the diagnosis of colorectal cancer (CRC), advanced adenomas (AAs), as well as Lynch-syndrome associated cancers. Additionally, a pre-planned analysis will evaluate the use of this liquid biopsy as a tool for molecular residual disease monitoring purposes.",[267,618,619,620,621,622,623,45,481,482,483,624,625,626,487,491,495,498,627],"Adenoma Colon","Adenoma Colon Polyp","Colon Adenoma","Colo-rectal Cancer","Colon Disease","Colon Neoplasm","LYN Gene Mutation","Mismatch Repair Deficiency","Mismatch Repair Gene Mutation","EPCAM Gene Mutation","2026-02-27",{"date":630,"type":92},"2026-03-04",{"date":632,"type":92},"2024-01-01",{"date":634,"type":23},"2031-08-15",{"name":529,"class":99},4,{"id":638,"slug":639,"hasResults":12,"nctId":640,"briefTitle":641,"officialTitle":642,"acronym":643,"eligibilityCriteria":644,"healthyVolunteers":12,"sex":18,"minAge":307,"maxAge":24,"enrollmentInfo":645,"targetDuration":4,"studyType":111,"phases":647,"briefSummary":648,"conditions":649,"keywords":650,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":653,"lastUpdatePostDateStruct":654,"startDateStruct":656,"completionDateStruct":658,"leadSponsor":660,"locationsCount":298},"100620685","study-aiming-to-test-whether-non-invasive-liquid-biopsies-can-safely-reduce-invasive-surveillance-methods-in-lynch-syndrome-100620685","NCT07360834","Study Aiming to Test Whether Non-invasive Liquid Biopsies Can Safely Reduce Invasive Surveillance Methods in Lynch Syndrome","Predicting Cancer Onset in Lynch Syndrome by Liquid Biopsies","PREDI-LYNCH","Inclusion Criteria:\n\n1. Participant must have signed a written informed consent prior to any trial specific procedures. When the patient is physically unable to give their written consent, a trusted person of their choice, independent from the investigator or the sponsor, can confirm in writing the patient's consent.\n2. Age 35-80\n3. Genetically confirmed class 4-5 (likely pathogenic (LP) or pathogenic (P) variant, respectively) in MLH1, MSH2, MSH6, or EPCAM gene.\n4. The participant should be insurance covered for the financial costs of the standard surveillance and healthcare related to LS, such as affiliated to Social Security System\n\nExclusion Criteria:\n\n1. Previously performed proctocolectomy or equivalent (entire colon and rectum removed)\n2. Active treatment for cancer within 2 years prior to inclusion.\n3. Checkpoint inhibitor therapy within 12 months\n4. Pregnancy\n5. Participants unwilling or unable to comply with the medical follow-up required by the trial because of geographic, familial, social, or psychological reasons.\n6. Persons deprived of their liberty or under protective custody or guardianship.",{"count":646,"type":23},2000,[113],"Lynch syndrome is an inherited genetic predisposition that increases the risk of developing several types of cancer, particularly colon and rectal cancers (colorectal cancer), as well as cancer of the uterine lining (endometrial cancer). It affects around 1 in 400 people in Europe.\n\nToday, surveillance mainly relies on examinations such as colonoscopy (an examination of the colon using a camera) or gynaecological evaluations, sometimes accompanied by biopsies (the removal of a small tissue sample for microscopic analysis). Although effective, these procedures are invasive and demanding; they can affect quality of life and discourage some individuals from adhering to their recommended surveillance programme.\n\nThe European project PREDI-LYNCH is exploring an additional pathway that is simpler and better tolerated. This project relies on \"liquid biopsies\", meaning tests performed on easily collected samples such as blood, urine, stool, and vaginal swabs for women with a uterus. The PREDI-LYNCH study aims to determine whether these non-invasive tests could enable personalised surveillance and potentially increase the interval between more burdensome procedures, while maintaining a high level of medical safety.",[45],[651,652],"Lynch Syndrome, hereditary cancer, MMR deficiency, Liquid biopsies, cancer early detection.","Lynch Syndrome, MMR deficiency, Liquid biopsies","2026-01-22",{"date":655,"type":92},"2026-01-23",{"date":657,"type":23},"2026-04-01",{"date":659,"type":23},"2030-12-01",{"name":661,"class":99},"UNICANCER",{"id":663,"slug":664,"hasResults":12,"nctId":665,"briefTitle":666,"officialTitle":667,"acronym":4,"eligibilityCriteria":668,"healthyVolunteers":17,"sex":18,"minAge":108,"maxAge":4,"enrollmentInfo":669,"targetDuration":4,"studyType":111,"phases":671,"briefSummary":672,"conditions":673,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":678,"lastUpdatePostDateStruct":679,"startDateStruct":680,"completionDateStruct":682,"leadSponsor":684,"locationsCount":686},"100400493","identifying-and-caring-for-individuals-with-inherited-cancer-syndrome-100400493","NCT04494945","Identifying and Caring for Individuals With Inherited Cancer Syndrome","Approaches to Identify and Care for Individuals With Inherited Cancer Syndromes","Inclusion Criteria:\n\n* ALL COHORTS: 18 years of age or older\n* Retrospective COHORT A: Per HIPAA waiver, Retrospective Cohort A will not actively consent\n* Retrospective COHORT A: Patients may or may not be diagnosed with cancer\n* Retrospective COHORT A: Patients have received genetic counseling in the past 5 years\n* Retrospective COHORT A: Patients have genetic variants that include BRCA1, BRCA2 and\u002For Lynch syndrome\n* COHORT A: Per Health Insurance Portability and Accountability Act (HIPAA) waiver, Cohort A returns survey as consent\n* COHORT A: Patients may or may not be diagnosed with cancer\n* COHORT A: Patients have received genetic counseling in the past 1 - 2 years\n* COHORT A: Patients have genetic variants that include BRCA1, BRCA2 and\u002For Lynch syndrome\n* COHORT A: INCLUSIVE of no contact list to exclude from Cohort B\n* COHORT B: Creation of secure Healthy Oregon Project (HOP) app account\n* COHORT B: Consent to this project, either hard or electronic signature\n* COHORT B: Consent to the HOP repository, either hard or electronic signature\n* COHORT B: Choosing to submit a deoxyribonucleic acid (DNA) sample\n* COHORT B: Patients diagnosed with any National Cancer Institute (NCI)-reportable cancers, including ductal carcinoma in situ (DCIS) and\u002For in situ breast cancer\n* COHORT B: Must have had an encounter within past twelve months\n* COHORT B: Exclude Cohort A\n* COHORT C: Creation of secure Hop app account\n* COHORT C: Consent to this project, either hard or electronic signature\n* COHORT C: Consent to the HOP repository, either hard or electronic signature\n* COHORT C: Choosing to submit a DNA sample",{"count":670,"type":23},27500,[113],"This trial examines approaches to identify and care for individuals with inherited cancer syndrome. The purpose of this study is to offer no cost genetic testing to the general public. Researchers hope to learn the value of providing broad, public-wide testing for high risk cancer types (like hereditary breast and ovarian cancer or Lynch syndromes) instead of only testing people whose families are known to be high risk.",[674,675,676,342,45,677],"BRCA1\u002F2-Associated Hereditary Breast and Ovarian Cancer Syndrome","Breast Ductal Carcinoma In Situ","Hematopoietic and Lymphoid System Neoplasm","Malignant Solid Neoplasm","2026-01-21",{"date":655,"type":92},{"date":681,"type":92},"2020-03-09",{"date":683,"type":23},"2026-03-31",{"name":685,"class":99},"OHSU Knight Cancer Institute",2,{"id":688,"slug":689,"hasResults":12,"nctId":690,"briefTitle":691,"officialTitle":692,"acronym":4,"eligibilityCriteria":693,"healthyVolunteers":17,"sex":18,"minAge":108,"maxAge":308,"enrollmentInfo":694,"targetDuration":4,"studyType":111,"phases":696,"briefSummary":697,"conditions":698,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":702,"lastUpdatePostDateStruct":703,"startDateStruct":705,"completionDateStruct":707,"leadSponsor":709,"locationsCount":129},"100609819","a-study-for-imaging-the-lower-gastrointestinal-tract-using-a-retro-tce-capsule-100609819","NCT07219537","A Study for Imaging the Lower Gastrointestinal Tract Using a Retro-TCE Capsule","Pilot Study for Imaging the Lower Gastrointestinal Tract Using a Retro-TCE Capsule","Inclusion Criteria:\n\n* Are 18 years of age or older.\n* Are healthy or with a confirmed diagnosis of Lynch Syndrome\n* Are capable of giving informed consent.\n* Are able to follow bowel prep instructions\n* Had a colonoscopy 0-24 months prior that did not show any abnormalities or individuals who report no gastrointestinal symptoms and no knowledge of any lower GI tract disease or abnormality and volunteer through Rally.\n\nExclusion Criteria:\n\n* Who are over 75 years of age or older\n* With a history or current diagnosis of colonic and\u002For anal strictures\n* With a current diagnosis of any bleeding disorders\n* Who currently use drugs that interfere with coagulation (excluding low-dose aspirin)\n* With a history or current diagnosis of colorectal cancer\n* With a history or current diagnosis of diverticulosis or diverticulitis\n* With any prior anorectal, colorectal, or colonic surgery\n* With a history of volvulus or torsion\n* Who are pregnant\n* With contraindications to bowel prep or colonoscopy\n* With severe acute inflammatory bowel disease\n* With large hemorrhoids or hemorrhoidal bleeding or banding",{"count":695,"type":23},30,[113],"The investigators have developed an inexpensive tool to take pictures in the lower GI tract without sedation and to look for signs of disease. The tool is a capsule, about the size of a fish oil or multi-vitamin supplement, attached to a string. The capsule and string are connected to a motor to allow the capsule to advance up the participant's lower GI tract. The capsule will be inserted into the participant's lower GI tract and advance upward via a slow spiral motion. The capsule is connected to an imaging system that saves and displays the images in real time.",[45,699,700,701],"Crohn Disease","Inflammatory Bowel Diseases","Healthy","2025-12-09",{"date":704,"type":92},"2025-12-16",{"date":706,"type":92},"2023-03-27",{"date":708,"type":23},"2028-12-31",{"name":710,"class":99},"Massachusetts General Hospital",{"id":712,"slug":713,"hasResults":12,"nctId":714,"briefTitle":715,"officialTitle":715,"acronym":716,"eligibilityCriteria":717,"healthyVolunteers":17,"sex":18,"minAge":108,"maxAge":4,"enrollmentInfo":718,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":720,"conditions":721,"keywords":731,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":740,"lastUpdatePostDateStruct":741,"startDateStruct":743,"completionDateStruct":745,"leadSponsor":747,"locationsCount":129},"100339653","liquid-biopsy-evaluation-and-repository-development-at-princess-margaret-100339653","NCT03702309","Liquid Biopsy Evaluation and Repository Development at Princess Margaret","LIBERATE","Inclusion Criteria:\n\n1. Patients with either histological confirmation of a solid tumor or hematological malignancy, OR patients identified as high-risk for cancer (based on identified aberration in cancer predisposition gene or on hormonal and\u002For family history without known aberration).\n2. Patient must be ≥ 18 years old.\n3. All patients must have signed and dated an informed consent form for this LIBERATE study.\n4. If patients are being co-consented for a separate primary research study listed in Appendix I, they must fulfill the eligibility criteria for that separate primary research study. If there is a discrepancy in the eligibility criteria between protocols, the separate primary research study's criteria take precedence.\n\nExclusion Criteria:\n\nNone",{"count":719,"type":23},2500,"The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the University Health Network's Princess Margaret Cancer Centre. Circulating cell-free nucleic acids (cfNA), including cell-free DNA (cfDNA) and cell-free RNA (cfRNA), are non-invasive, real-time biomarkers that can provide diagnostic and prognostic information before cancer diagnosis, during cancer treatment, and at disease progression. Cancer research scientists and clinicians at the Princess Margaret are interested in incorporating the collection of peripheral blood samples (\"liquid biopsies\") into research protocols as a means of non-invasively assessing tumor progression and response to treatment at multiple time points during a patient's course of disease.",[588,66,30,33,72,68,722,67,723,45,724,725,726,727,728,47,729,730],"Lymphoma","Mutation","Cowden Syndrome","BRCA1 Mutation","BRCA2 Mutation","Uterine Cancer","Myeloma","Head and Neck Cancer","Meningioma",[732,733,734,735,736,737,738,739],"High Risk","Liquid Biopsy","Circulating Tumor DNA","Blood","Molecular Profiling","Next Generation Sequencing","Solid Tumors","Hematological","2025-11-25",{"date":742,"type":92},"2025-11-26",{"date":744,"type":92},"2017-08-03",{"date":746,"type":23},"2026-07-06",{"name":748,"class":99},"University Health Network, Toronto",{"id":750,"slug":751,"hasResults":12,"nctId":752,"briefTitle":753,"officialTitle":753,"acronym":4,"eligibilityCriteria":754,"healthyVolunteers":17,"sex":18,"minAge":755,"maxAge":308,"enrollmentInfo":756,"targetDuration":4,"studyType":111,"phases":758,"briefSummary":759,"conditions":760,"keywords":762,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":770,"lastUpdatePostDateStruct":771,"startDateStruct":773,"completionDateStruct":775,"leadSponsor":777,"locationsCount":686},"100532870","urothelial-cancer-screening-in-individuals-with-lynch-syndrome-using-a-urine-tumor-dna-panel-ls-uro-study-100532870","NCT06218433","Urothelial Cancer Screening in Individuals With Lynch Syndrome Using a Urine Tumor DNA Panel (LS-URO Study)","Inclusion Criteria:\n\n* Willing and able to provide informed consent\n* Diagnosis of Lynch syndrome\n* Age 50 - 75 years at study recruitment\n\nExclusion Criteria:\n\n* Concurrent urothelial carcinoma","50 Years",{"count":757,"type":23},200,[113],"Lynch syndrome (LS) is an inherited cancer predisposition syndrome caused by pathogenic germline variants in DNA mismatch repair (MMR) genes. New cancer screening and diagnostic tools are urgently needed to identify LS-related cancers early enough for curative treatment. Urothelial cancers (comprising bladder and upper tract urothelial tumors) are the third most common cancer after colorectal and endometrial cancers in individuals with LS. Up to one in four LS individuals will develop urothelial cancer during their lifetime, with the risk varying based on the defective MMR gene. In this clinical trial, we will employ urine tumor DNA (utDNA) to identify asymptomatic urothelial cancers in Lynch syndrome patients, and to investigate the potential benefits of urine tumor DNA based screening in this high-risk population.",[761,45],"Urothelial Carcinoma",[451,763,117,764,765,766,767,768,769],"Hereditary cancer syndrome","Urothelial neoplasms","Bladder neoplasms","Upper tract urothelial neoplasms","Urogenital diseases","Liquid biopsies","Urine tumor DNA","2025-11-17",{"date":772,"type":92},"2025-11-18",{"date":774,"type":92},"2023-04-10",{"date":776,"type":23},"2034-12-31",{"name":778,"class":99},"Tampere University Hospital",{"id":780,"slug":781,"hasResults":12,"nctId":782,"briefTitle":783,"officialTitle":783,"acronym":784,"eligibilityCriteria":785,"healthyVolunteers":12,"sex":18,"minAge":108,"maxAge":4,"enrollmentInfo":786,"targetDuration":4,"studyType":111,"phases":788,"briefSummary":789,"conditions":790,"keywords":794,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":807,"lastUpdatePostDateStruct":808,"startDateStruct":810,"completionDateStruct":812,"leadSponsor":814,"locationsCount":298},"100209193","phase-3-the-cancer-of-the-pancreas-screening-5-caps5study-100209193","NCT02000089","The Cancer of the Pancreas Screening-5 CAPS5)Study","CAPS5","Inclusion Criteria:\n\n* Hereditary Pancreatitis or\n* Peutz-Jeghers Syndrome or\n* Strong family history of pancreas cancer on one side of the family tree or\n* Confirmed germline mutation carrier (BRCA2, FAMMM (CDKN2A\u002Fp16), PALB2, BRCA1, ATM, HNPCC, Lynch Syndrome (hMLH1, hMSH2, PMS2, hMSH6, EpCAM) PRSS1, PRSS2, R122H, N291l, SPINK1, CFTR\n* Endoscopic evaluation of pancreas scheduled\n\nExclusion Criteria:\n\n* Medical comorbidities or coagulopathy that contraindicate endoscopy\n* Prior surgery that prevent optimal endoscopic ultrasound such as partial or complete gastrectomy with Bilroth or Roux-en-Y anastomosis\n* Stricture or obstruction in the upper GI tract that does not allow passage of the echoendoscope\n* Poor performance status\n* Inability to provide informed consent\n* Pregnancy.",{"count":787,"type":23},9000,[312],"Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.",[407,791,792,793,45],"Peutz-Jeghers Syndrome (PJS)","Gene Mutation","Germline Mutation Carrier",[795,796,797,798,799,800,801,802,45,803,804,805,806],"familial pancreas cancer","(Peutz-Jeghers Syndrome) PJS","Breast cancer (BRCA) 2","Partner and Locator of BRCA2 (PALB2)","Familial Atypical Multiple Mole- Melanoma (FAMMM)","p16, CDKN2A","Breast Cancer (BRCA)1","(hereditary non-polyposis colorectal cancer or Lynch syndrome) HNPCC","hereditary pancreatitis","Protease Serine (PRSS)","Chymotrypsin C (CTRC)","Ataxia Telangiectasia Mutated(ATM)","2025-10-08",{"date":809,"type":92},"2025-10-09",{"date":811,"type":92},"2014-01-06",{"date":813,"type":23},"2029-06",{"name":815,"class":99},"Johns Hopkins University"]